BioCAIR: Biomarkers of t-cell activity in tumours and immunotherapy response
In order to propose a targeted and efficient treatment of most advanced non-small cell lung cancer (NSCLC), the BioCAIR project proposes to identify new biomarkers of clinical response to immunotherapies and develop innovative imaging diagnostic tools. The consortium is a public-private partnership with skills suitable for molecular imaging studies, from molecular chemistry to preclinical imaging in close vicinity with several hospital clinical departments.
|Cyril BERTHET, ONCODESIGN/Pharmimage Collab. CHU Besançon, CGFL, ICMUB, LNC, LIIC, Diaclone|